Evidence map›Paper›PMID 39980630›Full record

ArticleMaterials today. Bio2025

Physically engineered extracellular vesicles targeted delivering miR-21-5p to promote renoprotection after renal ischemia-reperfusion injury.

Di Wu, Wenjie Ma, Liucheng Wang, Chengcheng Long, Silin Chen, Jingyu Liu, Yiguan Qian, Jun Zhao, Changcheng Zhou, Ruipeng Jia

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Di WuDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Wenjie MaDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Liucheng WangDepartment of Urology, Lianshui People's Hospital, Kangda College Affiliated to Nanjing Medical University, Jiang Su, 223400, China.
Chengcheng LongDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Silin ChenDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Jingyu LiuDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Yiguan QianDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Jun ZhaoDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Changcheng ZhouDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.
Ruipeng JiaDepartment of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury (AKI) resulting from ischemia-reperfusion injury (IRI) is a common challenge in various clinical practices, yet effective therapies remain elusive. Endothelial injury plays a crucial role in the pathogenesis of renal IRI. Endothelial progenitor cells (EPCs) derived extracellular vesicles (EVs) hold promise as cell-free therapies for treating renal IRI; however, their efficacy is limited by low delivery efficiency. In this study, we developed neutrophils (NEs) membrane-modified EVs (N-EVs) by exploiting the natural properties of NEs to target damaged endothelium. N-EVs inherited the characteristic membrane proteins of NEs along with the biological functions of EPCs-EVs. Results from

Indexed as

Cell membraneEngineeringExtracellular vesiclemiRNAsNeutrophilRenoprotection

Identifiers

PMID39980630
PMCPMC11840549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.